American Journal of Transplantation · Nov 12, 2026

Risk Assessment for Transmission of Porcine Endogenous Retrovirus in Clinical Xenotransplantation

By Fishman JA, Rudenko L, Sachs DH

Porcine to human xenotransplantation clinical trials are underway. Concerns remain regarding potential transmission of infections including porcine endogenous retroviruses (PERVs) to human xenotransplant recipients with adverse health outcomes. All pigs contain subtypes PERV-A and PERV-B, and some also carry PERV-C. Human cells carry receptors for PERV-A and -B but not for PERV-C. PERV-A can recombine with PERV-B to form PERV-A/B hybrids and recombine with PERV-C to form PERV-A/C hybrids in vivo and in vitro. No evidence of PERV transmission to non-human primates or other laboratory animals, human primary cells, or to humans from surgical or non-surgical exposures has been reported, although transmission of PERV A/C hybrids has been observed in certain permissive transformed human cell lines. PERV inactivation has been achieved via genetic editing in some pig lines. Here, we review the data related to the potential for PERV infection in human xenograft recipients based on published data on PERV structure and host cellular and species tropisms. Despite the lack of evidence regarding transmissibility of PERVs to humans, we advocate the rigorous monitoring of patients and, possibly, their close contacts in initial clinical trials for possible PERV transmission following xenotransplantation.

doi.org/10.1016/j.ajt.2026.11.002Open accessPubMed 43020378Mechanisms

AgingResearch.News